Colchicine treatment in community healthcare setting to prevent severe COVID-19

Ann Rheum Dis. 2022 Oct;81(10):e198. doi: 10.1136/annrheumdis-2020-218759. Epub 2020 Aug 27.

Authors

Emanuel Della-Torre^{1

2}, Giuseppe A Ramirez^{3

2}, Lorenzo Dagna^{3

2}, Moreno Tresoldi⁴

Affiliations

¹ Università Vita-Salute San Raffaele, San Raffaele Scientific Institute, Milan, Italy dellatorre.emanuel@hsr.it.
² Unit of Immunology, Rheumatology, Allergy, and Rare Diseases (UnIRAR), San Raffaele Scientific Institute, Milan, Italy.
³ Università Vita-Salute San Raffaele, San Raffaele Scientific Institute, Milan, Italy.
⁴ Unit of General Medicine and Advanced Care, San Raffaele Scientific Institute, Milan, Italy.

PMID: 32855152
DOI: 10.1136/annrheumdis-2020-218759

No abstract available

Keywords: anti-inflammatory agents; health care; inflammation; non-steroidal; outcome assessment.

Publication types

Letter
Comment

MeSH terms

Anti-Inflammatory Agents, Non-Steroidal
COVID-19*
Colchicine / therapeutic use
Community Health Services
Humans

Substances

Anti-Inflammatory Agents, Non-Steroidal
Colchicine